Free tool
FAERS Monitor: Ifex/Mesnex Kit
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019763 or its brand name (Ifex/Mesnex Kit, Ifosfamide, Mesna). Reports on generic versions are filed under their own applications.
Reports
21,791
Serious
21,243
97% of reports
Hospitalization
6,750
Death reported
4,473
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,896
- febrile neutropenia2,740
- disease progression2,145
- neutropenia1,931
- drug ineffective1,626
- thrombocytopenia1,578
- anaemia1,277
- pyrexia1,028
- product use in unapproved indication964
- sepsis888
- pancytopenia836
- infection822
- vomiting764
- nausea761
- malignant neoplasm progression752
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 208 |
| 2005 | 200 |
| 2006 | 145 |
| 2007 | 219 |
| 2008 | 236 |
| 2009 | 249 |
| 2010 | 284 |
| 2011 | 580 |
| 2012 | 686 |
| 2013 | 514 |
| 2014 | 410 |
| 2015 | 893 |
| 2016 | 843 |
| 2017 | 1,169 |
| 2018 | 1,263 |
| 2019 | 1,448 |
| 2020 | 1,833 |
| 2021 | 1,630 |
| 2022 | 2,092 |
| 2023 | 2,275 |
| 2024 | 1,896 |
| 2025 | 1,561 |
| 2026 | 1,155 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,032,368 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 2,740 | 41.5 | 40.1 | 104,228 |
| disease progressionSignal | 2,145 | 17.8 | 17.1 | 33,572 |
| pancytopeniaSignal | 836 | 14.6 | 13.7 | 10,482 |
| neutropeniaSignal | 1,931 | 13.9 | 13.3 | 22,908 |
| thrombocytopeniaSignal | 1,578 | 13.8 | 13.2 | 18,558 |
| sepsisSignal | 888 | 7.7 | 7.3 | 5,189 |
| malignant neoplasm progressionSignal | 752 | 7.1 | 6.6 | 3,949 |
| anaemiaSignal | 1,277 | 6.5 | 6.2 | 5,951 |
| infectionSignal | 822 | 5.5 | 5.1 | 3,031 |
| product use in unapproved indicationSignal | 964 | 3.8 | 3.5 | 1,970 |
| off label useSignal | 2,896 | 3.2 | 3.1 | 4,552 |
| pyrexiaSignal | 1,028 | 2.9 | 2.7 | 1,271 |
| vomiting | 764 | 1.6 | 1.5 | 161 |
| drug ineffective | 1,626 | 1.2 | 1.1 | 53 |
| nausea | 761 | 0.9 | 0.9 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.